Caricamento...
Novel non-AR therapeutic targets in castrate resistant prostate cancer
Castrate resistant prostate cancer (CRPC) remains a disease with significant morbidity and mortality. The recent approval of abiraterone and enzalutamide highlight the improvements which can be made targeting the androgen receptor (AR) axis. Nonetheless, resistance inevitably develops and there is c...
Salvato in:
| Pubblicato in: | Transl Androl Urol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
AME Publishing Company
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4708177/ https://ncbi.nlm.nih.gov/pubmed/26816739 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2223-4683.2013.09.09 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|